Sign Up to like & get
recommendations!
1
Published in 2017 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-017-0381-2
Abstract: Internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations of the FMS-like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid leukemia (AML) and confer a poor prognosis.…
read more here.
Keywords:
targeting flt3;
future targeting;
flt3 activation;
activation aml ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Blood"
DOI: 10.1182/blood.2021015246
Abstract: Fms like tyrosine kinase 3 (FLT3) is often overexpressed or constitutively activated by internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations in acute myeloid leukemia (AML). Despite the use of receptor tyrosine kinase…
read more here.
Keywords:
flt3;
20d9 adc;
aml;
targeting flt3 ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007486
Abstract: Key Points • JAK2, ABL, and MAPK signaling drive adaptive resistance to FLT3 inhibitors.• Polypharmacological targeting of FLT3, JAK2, ABL, and MAPK signaling provides a durable response in AML.
read more here.
Keywords:
flt3 inhibitors;
adaptive resistance;
jak2 abl;
targeting flt3 ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "OncoTargets and Therapy"
DOI: 10.2147/ott.s384293
Abstract: Abstract FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid leukemia (AML) patients. The presence of FLT3-ITD (internal tandem duplication, 20–25%) mutation and, to a lesser extent, FLT3-TKD (tyrosine kinase domain,…
read more here.
Keywords:
flt3;
acute myeloid;
myeloid leukemia;
targeting flt3 ... See more keywords